CR10047A - Compuestos orgánicos - Google Patents
Compuestos orgánicosInfo
- Publication number
- CR10047A CR10047A CR10047A CR10047A CR10047A CR 10047 A CR10047 A CR 10047A CR 10047 A CR10047 A CR 10047A CR 10047 A CR10047 A CR 10047A CR 10047 A CR10047 A CR 10047A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compounds
- inhibitors
- formula
- treatment
- organic compounds
- Prior art date
Links
- 150000002894 organic compounds Chemical class 0.000 title 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 102000014400 SH2 domains Human genes 0.000 abstract 1
- 108050003452 SH2 domains Proteins 0.000 abstract 1
- 210000004204 blood vessel Anatomy 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000023589 ischemic disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
Abstract
Los compuestos de la Fórmula: son inhibidores de las fosfatasas de proteína tirosina (PTPasas), y por lo tanto, se pueden emplear para el tratamiento de las condiciones mediadas por la actividad de la PTPasa. Los compuestos de la presente invención también se pueden emplear como inhibidores de otras enzimas caracterizadas por una región de enlace de fosfotirosina, tal como el dominio SH2. De acuerdo con lo anterior, los compuestos de la Fórmula (I) se pueden emplear para la prevención y/o el tratamiento de resistencia a la insulina asociada con obesidad, intolerancia a la glucosa, diabetes mellitus, hipertensión y enfermedades isquémicas de los vasos sanguíneos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74849205P | 2005-12-08 | 2005-12-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR10047A true CR10047A (es) | 2008-10-16 |
Family
ID=37903424
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR10047A CR10047A (es) | 2005-12-08 | 2008-06-05 | Compuestos orgánicos |
Country Status (23)
Country | Link |
---|---|
US (1) | US8252820B2 (es) |
EP (1) | EP1963293A1 (es) |
JP (1) | JP2009518419A (es) |
KR (1) | KR20080075218A (es) |
CN (1) | CN101336235A (es) |
AR (1) | AR058285A1 (es) |
AU (1) | AU2006321902B2 (es) |
BR (1) | BRPI0619567A2 (es) |
CA (1) | CA2631007A1 (es) |
CR (1) | CR10047A (es) |
EC (1) | ECSP088509A (es) |
GT (1) | GT200800093A (es) |
IL (1) | IL191711A0 (es) |
MA (1) | MA30018B1 (es) |
NO (1) | NO20083030L (es) |
NZ (1) | NZ568663A (es) |
PE (2) | PE20100470A1 (es) |
RU (1) | RU2008127262A (es) |
TN (1) | TNSN08248A1 (es) |
TW (1) | TW200800928A (es) |
UA (1) | UA94921C2 (es) |
WO (1) | WO2007067612A1 (es) |
ZA (1) | ZA200804489B (es) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080293782A1 (en) * | 2005-12-08 | 2008-11-27 | David Barnes | 1,1,3-Trioxo-1,2,5-Thiadiazolidines and Their Use as Ptp-Ases Inhibitors |
KR20080074970A (ko) * | 2005-12-08 | 2008-08-13 | 노파르티스 아게 | 단백질 티로신 포스파타제 (ptpase)에 의해 매개되는질병의 치료에 유용한 1,2,5-티아졸리딘 유도체 |
BRPI0710182A2 (pt) * | 2006-03-31 | 2012-08-07 | Novartis Ag | compostos orgÂnicos. |
DE102007015169A1 (de) * | 2007-03-27 | 2008-10-02 | Universität des Saarlandes Campus Saarbrücken | 17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US20130109887A1 (en) * | 2010-08-26 | 2013-05-02 | Albermarle Corporation | Processes for producing 1-bromo-2- (cyclopropyl methoxy)-5-fluoro-4-methoxybenzene |
US9040525B2 (en) | 2010-10-08 | 2015-05-26 | Mochida Pharmaceutical Co., Ltd. | Cyclic amide derivative |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
JPWO2012147516A1 (ja) | 2011-04-28 | 2014-07-28 | 持田製薬株式会社 | 環状アミド誘導体 |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2017078499A2 (ko) * | 2015-11-06 | 2017-05-11 | 경북대학교 산학협력단 | 단백질 타이로신 탈인산화효소 억제제를 포함하는 신경염증성 질환의 예방 또는 치료용 조성물 |
PE20210372A1 (es) * | 2018-06-21 | 2021-02-26 | Abbvie Inc | Inhibidores de proteina tirosina fosfatasa y sus metodos de uso |
MX2021003240A (es) | 2018-09-18 | 2021-05-12 | Basf Se | Compuestos de diaminotriazina. |
AU2020234712A1 (en) * | 2019-03-14 | 2021-09-09 | Abbvie Inc. | Protein tyrosine phosphatase inhibitors and methods of use thereof |
EP4077291A1 (en) * | 2019-12-18 | 2022-10-26 | Calico Life Sciences LLC | Protein tyrosine phosphatase inhibitors and methods of use thereof |
WO2021127586A1 (en) * | 2019-12-20 | 2021-06-24 | Calico Life Sciences Llc | Protein tyrosine phosphatase degraders and methods of use thereof |
EP4211122A1 (en) * | 2020-09-11 | 2023-07-19 | Calico Life Sciences LLC | Protein tyrosine phosphatase inhibitors and methods of use thereof |
EP4284786A1 (en) | 2021-01-27 | 2023-12-06 | Basf Se | Diaminotriazine compounds |
JP2024509962A (ja) * | 2021-03-11 | 2024-03-05 | カムクワット バイオサイエンシーズ インコーポレイテッド | 複素環及びその使用 |
CA3236854A1 (en) * | 2021-11-11 | 2023-05-19 | Andrew Bogdan | Protein tyrosine phosphatase inhibitors and methods of use thereof |
CA3236853A1 (en) * | 2021-11-11 | 2023-05-19 | Andrew Bogdan | Protein tyrosine phosphatase inhibitors and methods of use thereof |
WO2023147531A1 (en) * | 2022-01-31 | 2023-08-03 | Bristol-Myers Squibb Company | Inhibitors of protein tyrosine phosphatase, compositions, and methods of use |
TW202337459A (zh) * | 2022-02-02 | 2023-10-01 | 美商耐瑞歐醫療公司 | 蛋白酪胺酸磷酸酶抑制劑及其用途 |
WO2023150150A1 (en) * | 2022-02-02 | 2023-08-10 | Nerio Therapeutics, Inc. | Protein tyrosine phosphatase inhibitors and uses thereof |
WO2023150523A1 (en) * | 2022-02-02 | 2023-08-10 | Nerio Therapeutics, Inc. | Protein tyrosine phosphatase inhibitors and uses thereof |
WO2024059041A1 (en) * | 2022-09-13 | 2024-03-21 | Kumquat Biosciences, Inc. | Benzo-fused n-heterocycles and uses thereof |
WO2024067802A1 (zh) * | 2022-09-30 | 2024-04-04 | 深圳众格生物科技有限公司 | 蛋白酪氨酸磷酸酶抑制剂及其制备方法和医药用途 |
WO2024102794A1 (en) * | 2022-11-09 | 2024-05-16 | Bristol-Myers Squibb Company | Inhibitors of protein tyrosine phosphatase, compositions, and methods of use |
WO2024137727A1 (en) * | 2022-12-21 | 2024-06-27 | Bristol-Myers Squibb Company | 1,2,4-thiazolidin-3-one-1,1-dioxide inhibitors of protein tyrosine phosphatase, compositions, and methods of use |
WO2024141015A1 (en) * | 2022-12-30 | 2024-07-04 | Insilico Medicine Ip Limited | Protein tyrosine phosphatase inhibitors and uses thereof |
CN117343052B (zh) * | 2023-12-04 | 2024-02-06 | 英矽智能科技(上海)有限公司 | 蛋白酪氨酸磷酸酶抑制剂及其应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002254342A1 (en) * | 2001-03-23 | 2002-10-08 | The Board Of Trustees Of The University Of Illinois | Compounds capable of modulating the activity of multidrug transporters and therapeutic use of the same |
PL372848A1 (en) * | 2002-04-03 | 2005-08-08 | Novartis Ag | 5-substituted 1,1-dioxo-[1,2,5]thiazolidine-3-one derivatives as ptpase 1b inhibitors |
GB0225986D0 (en) * | 2002-11-07 | 2002-12-11 | Astrazeneca Ab | Chemical compounds |
GB0227813D0 (en) * | 2002-11-29 | 2003-01-08 | Astrazeneca Ab | Chemical compounds |
EP1594497B1 (en) * | 2002-12-30 | 2009-05-27 | Vertex Pharmaceuticals Incorporated | Sulfhydantoins as phosphate isosteres for use as phosphatase inhibitors in the treatment of cancer and autoimmune disorders |
US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
US7141596B2 (en) * | 2003-10-08 | 2006-11-28 | Incyte Corporation | Inhibitors of proteins that bind phosphorylated molecules |
US20080293782A1 (en) | 2005-12-08 | 2008-11-27 | David Barnes | 1,1,3-Trioxo-1,2,5-Thiadiazolidines and Their Use as Ptp-Ases Inhibitors |
UA94724C2 (en) * | 2005-12-08 | 2011-06-10 | Новартис Аг | Thiadiazolidinone derivatives as antidiabetic agents |
KR20080074970A (ko) | 2005-12-08 | 2008-08-13 | 노파르티스 아게 | 단백질 티로신 포스파타제 (ptpase)에 의해 매개되는질병의 치료에 유용한 1,2,5-티아졸리딘 유도체 |
BRPI0710182A2 (pt) | 2006-03-31 | 2012-08-07 | Novartis Ag | compostos orgÂnicos. |
-
2006
- 2006-06-12 UA UAA200807752A patent/UA94921C2/ru unknown
- 2006-12-06 PE PE2010000301A patent/PE20100470A1/es not_active Application Discontinuation
- 2006-12-06 RU RU2008127262/04A patent/RU2008127262A/ru not_active Application Discontinuation
- 2006-12-06 EP EP06844889A patent/EP1963293A1/en not_active Withdrawn
- 2006-12-06 NZ NZ568663A patent/NZ568663A/en not_active IP Right Cessation
- 2006-12-06 JP JP2008544464A patent/JP2009518419A/ja active Pending
- 2006-12-06 AR ARP060105391A patent/AR058285A1/es not_active Application Discontinuation
- 2006-12-06 WO PCT/US2006/046542 patent/WO2007067612A1/en active Application Filing
- 2006-12-06 PE PE2006001572A patent/PE20071094A1/es not_active Application Discontinuation
- 2006-12-06 CA CA002631007A patent/CA2631007A1/en not_active Abandoned
- 2006-12-06 AU AU2006321902A patent/AU2006321902B2/en not_active Ceased
- 2006-12-06 BR BRPI0619567-9A patent/BRPI0619567A2/pt not_active IP Right Cessation
- 2006-12-06 KR KR1020087016433A patent/KR20080075218A/ko not_active Application Discontinuation
- 2006-12-06 CN CNA2006800524439A patent/CN101336235A/zh active Pending
- 2006-12-06 US US12/096,432 patent/US8252820B2/en not_active Expired - Fee Related
- 2006-12-07 TW TW095145872A patent/TW200800928A/zh unknown
-
2008
- 2008-05-26 IL IL191711A patent/IL191711A0/en unknown
- 2008-05-27 ZA ZA200804489A patent/ZA200804489B/xx unknown
- 2008-06-02 MA MA30986A patent/MA30018B1/fr unknown
- 2008-06-05 CR CR10047A patent/CR10047A/es not_active Application Discontinuation
- 2008-06-06 GT GT200800093A patent/GT200800093A/es unknown
- 2008-06-06 TN TNP2008000248A patent/TNSN08248A1/en unknown
- 2008-06-06 EC EC2008008509A patent/ECSP088509A/es unknown
- 2008-07-04 NO NO20083030A patent/NO20083030L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
RU2008127262A (ru) | 2010-01-20 |
WO2007067612A1 (en) | 2007-06-14 |
ECSP088509A (es) | 2008-07-30 |
IL191711A0 (en) | 2008-12-29 |
EP1963293A1 (en) | 2008-09-03 |
AR058285A1 (es) | 2008-01-30 |
US8252820B2 (en) | 2012-08-28 |
NO20083030L (no) | 2008-08-28 |
ZA200804489B (en) | 2009-08-26 |
GT200800093A (es) | 2010-07-09 |
BRPI0619567A2 (pt) | 2011-10-04 |
TW200800928A (en) | 2008-01-01 |
PE20071094A1 (es) | 2008-01-07 |
AU2006321902B2 (en) | 2011-11-10 |
KR20080075218A (ko) | 2008-08-14 |
MA30018B1 (fr) | 2008-12-01 |
PE20100470A1 (es) | 2010-07-13 |
TNSN08248A1 (en) | 2009-10-30 |
NZ568663A (en) | 2011-07-29 |
CA2631007A1 (en) | 2007-06-14 |
JP2009518419A (ja) | 2009-05-07 |
UA94921C2 (en) | 2011-06-25 |
CN101336235A (zh) | 2008-12-31 |
US20100035942A1 (en) | 2010-02-11 |
AU2006321902A1 (en) | 2007-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR10047A (es) | Compuestos orgánicos | |
ECSP088506A (es) | Derivados de tiadiazol como agentes antidiabeticos | |
GT200600429A (es) | Compuestos organicos | |
AR066820A1 (es) | Compuestos de tiadiazolidin-3 ona | |
WO2010008739A3 (en) | Aryl gpr119 agonists and uses thereof | |
WO2010029089A3 (en) | Combination therapy for the treatment of diabetes and related conditions | |
ATE550329T1 (de) | Heterobicyclische sulfonamidderivate zur behandlung von diabetes | |
UY31952A (es) | 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim | |
TW200745047A (en) | Heterocyclic compounds | |
GEP20135724B (en) | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for treatment or prevention of diabetes | |
EA200801897A1 (ru) | Ингибиторы mnk2 на основе 8-гетероарилпурина для лечения метаболических нарушений | |
UY29457A1 (es) | Compuestos novedosos de derivados de aminosulfonilo | |
TNSN08247A1 (en) | 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors | |
EA200800087A1 (ru) | Генетические варианты гена tcf7l2 как диагностические маркеры риска возникновения сахарного диабета ii типа | |
DE602004007693D1 (de) | (3-oxo-3,4-dihydro-chinoxalin-2-yl-amino)-benzamid-derivate und verwandte verbindungen als glykogen-phosphorylase-hemmer zur behandlung von diabetes und adipositas | |
UA95244C2 (ru) | Соединения и способ модулирования активности киназ, и показания для их применения | |
MX2010003449A (es) | Derivado de quinolona. | |
WO2009042435A8 (en) | Pyridin-2 -yl-amino-i, 2, 4 -thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus | |
NO20081253L (no) | Klebepreparat inneholdende bisopropol | |
ATE534637T1 (de) | 5-substituierte 1,1-dioxo- 1,2,5 thiazolidin-3- onderivate als ptpase 1b hemmer | |
EA201000391A1 (ru) | Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция | |
CY1112009T1 (el) | Παρασκευη συζυγων ινσουλινης | |
DK1824501T3 (da) | Proteinhydrolysat med antidiabetisk virkning | |
WO2005086804A3 (en) | Modulation of ace2 expression | |
DE602005019770D1 (de) | Medizinische zusammensetzung zur behandlung von krebs oder diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |